Aditya Bardia, MD, MPH, FASCO

Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.

Articles

A Brief Overview of Treatment Options for Triple-Negative Breast Cancer

September 13th 2022

Expert oncologist Aditya Bardia, MD, MPH, shares his perspective on mainstay treatment options for patients diagnosed with metastatic triple-negative breast cancer.

Promising Strategies for Assessing Risk and Detecting Recurrence Earlier

August 31st 2022

Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.

Technical and Logistical Challenges Concerning the use of ctDNA Monitoring

August 31st 2022

Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.

Practical Clinical Applications for ctDNA Assessment

August 31st 2022

Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.

Data Review: ctDNA Monitoring in Patients with Breast Cancer

August 31st 2022

Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.

Clinical Evidence Supporting the use of ctDNA to Detect Recurrence

August 31st 2022

A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.

Best Practices for Assessing Risk of Recurrence in Patients with Breast Cancer

August 31st 2022

Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v